Preclinical studies of RUC-4, a novel platelet αIIbβ3 antagonist, in non-human primates and with human platelets

AbstractIntroduction:We are developing the novel αIIbβ3 antagonist, RUC-4, for subcutaneously (SC)-administered first-point-of-medical-contact treatment for ST segment elevation myocardial infarction (STEMI).Methods:We studied the (1) pharmacokinetics (PK) of RUC-4 at 1.0, 1.93, and 3.86 mg/kg intra...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Spandana Vootukuri, Jihong Li, Mark Nedelman, Craig Thomas, Jiang-Kang Jiang, Mariana Babayeva, Barry S. Coller
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Cambridge University Press 2019-06-01
coleção:	Journal of Clinical and Translational Science
Assuntos:	Platelets antiplatelet therapy αIIbβ3 antagonists ST segment elevation myocardial infarction (STEMI) integrin receptors
Acesso em linha:	https://www.cambridge.org/core/product/identifier/S2059866119003820/type/journal_article
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!